Malaria drug combo safety checked in tiny study
NCT ID NCT04080895
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study aimed to see how two common malaria drugs, artemether-lumefantrine and amodiaquine, interact in the body. It enrolled only 8 healthy adults in Thailand and was terminated early. The goal was to measure drug levels and safety when given alone or together.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- artemether-lumefantrine and amodiaquine
- What this could lead to
- If successful, this could help doctors understand how to safely combine these two malaria treatments.
- What could go wrong
- This is a very early, small study in healthy people, not patients. It was terminated early, so results are limited and may not apply to real-world use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DRUG COMBINATION are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Faculty of Tropical Medicine, Mahidol University
Bangkok, 10400, Thailand
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Does injection location matter for a new Weight-Loss drug? a trial investigates
- Which medical adhesive stays put longest without itching? a head-to-head test in healthy women.
- Avocado at breakfast: a secret weapon for blood sugar and fullness?
- New eye drop aims to tame ocular pain in early trial
- Could a formula closer to breast milk boost baby development?
- Could a daily probiotic help you feel fuller and eat less?